This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
The inspection closed with the facility receiving an inspection classification of NAI
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Granules now has a total of 58 ANDA approvals from US FDA
Subscribe To Our Newsletter & Stay Updated
